Arrowhead Pharmaceuticals Inc (ARWR)

Cash ratio

Sep 30, 2025 Jun 30, 2025 Mar 31, 2025 Dec 31, 2024 Sep 30, 2024 Jun 30, 2024 Mar 31, 2024 Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022 Dec 31, 2021 Sep 30, 2021 Jun 30, 2021 Mar 31, 2021 Dec 31, 2020
Cash and cash equivalents US$ in thousands 88,706 129,793 185,709 53,889 102,685 69,399 127,704 58,215 110,891 105,334 134,959 202,249 108,005 139,439 86,408 91,587 184,434 325,981 372,377 139,921
Short-term investments US$ in thousands 830,660 770,579 911,700 499,046 578,276 367,272 395,410 162,064 292,735 346,369 346,046 299,582 268,391 277,057 315,487 238,547 183,355 190,331 204,941 165,406
Total current liabilities US$ in thousands 195,487 194,530 220,541 93,758 103,168 96,714 65,175 63,723 105,456 70,227 87,151 66,281 74,099 128,212 138,857 137,032 146,536 195,434 167,188 25,094
Cash ratio 4.70 4.63 4.98 5.90 6.60 4.52 8.03 3.46 3.83 6.43 5.52 7.57 5.08 3.25 2.89 2.41 2.51 2.64 3.45 12.17

September 30, 2025 calculation

Cash ratio = (Cash and cash equivalents + Short-term investments) ÷ Total current liabilities
= ($88,706K + $830,660K) ÷ $195,487K
= 4.70